Home207940 • KRX
add
Samsung Biologics Co Ltd
Previous close
₩1,514,000.00
Day range
₩1,514,000.00 - ₩1,533,000.00
Year range
₩982,000.00 - ₩1,987,000.00
Market cap
70.73T KRW
Avg Volume
43.37K
P/E ratio
41.25
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
| (KRW) | Mar 2026info | Y/Y change |
|---|---|---|
Revenue | 1.26T | -3.18% |
Operating expense | 99.00B | -58.99% |
Net income | 469.00B | 24.88% |
Net profit margin | 37.31 | 28.97% |
Earnings per share | — | — |
EBITDA | — | — |
Effective tax rate | 26.83% | — |
Balance Sheet
Total assets
Total liabilities
| (KRW) | Mar 2026info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.62T | 26.05% |
Total assets | 12.00T | -31.21% |
Total liabilities | 4.07T | -33.86% |
Total equity | 7.92T | — |
Shares outstanding | — | — |
Price to book | — | — |
Return on assets | 12.60% | — |
Return on capital | 16.88% | — |
Cash Flow
Net change in cash
| (KRW) | Mar 2026info | Y/Y change |
|---|---|---|
Net income | 469.00B | 24.88% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Founded
2011
Website
Employees
4,770
